VRTX

Vertex Pharmaceuticals closed at $514.70, up 2.54%, outperforming the S&P 500's 0.28% gain. The company is expected to report earnings on November 2, 2026, with forecasted EPS of $4.92 (up 2.5% YoY) and revenue of $3.4 billion (up 10.57% YoY). VRTX holds a Zacks Rank #3 (Hold) with a Forward P/E of 26.53, trading at a premium to its industry average.

The article explains how to identify medical stocks positioned for positive earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) filter. It demonstrates that combining positive ESP with a Zacks Rank #3 or better has historically resulted in positive earnings surprises 70% of the time with 28.3% average annual returns. Two medical stocks are highlighted as examples: Illumina with a +9.16% ESP and Buy rating, and Vertex Pharmaceuticals with a +4.98% ESP and Hold rating.

Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

Vertex Pharmaceuticals (VRTX) has been trending on Zacks.com's most searched stocks list. The company shows modest earnings growth of +2.5% for the current quarter and +2.7% for the fiscal year, with revenue growth projected at +10.1% for the current year.

However, the stock has underperformed the S&P 500 over the past month (-1.5% vs +1.4%) and carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. The stock is trading at a premium to peers with a D valuation grade.

Vertex Pharmaceuticals (VRTX) closed at $508.75, up 2.06%, outperforming the S&P 500's 0.33% gain. However, the stock has declined 2.88% over the past month.

The company is scheduled to report earnings on November 2, 2026, with projected EPS of $4.84 (up 0.83% YoY) and quarterly revenue of $3.4 billion (up 10.49% YoY). Despite positive revenue growth expectations, the stock holds a Zacks Rank of #3 (Hold) with a Forward P/E of 26.52, trading at a premium to its industry average.

Vertex Pharmaceuticals is diversifying beyond its core cystic fibrosis business through its $10 billion acquisition of Crinetics Pharmaceuticals. The company now has Palsonify (approved for acromegaly) and Atumelnant (in development for rare hormonal disorders) with estimated peak revenue potential exceeding $5 billion. Combined with other pipeline candidates like povetacicept and gene-editing medicine Casgevy, Vertex's hormone disorder franchise could become a significant growth driver over the medium term.

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline.

Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

Vertex Pharmaceuticals (VRTX) outperformed the broader market on October 9, 2026, gaining 1.36% to $510.08, compared to the S&P 500's 0.6% gain. However, the stock has declined 2.2% over the past month.

The company is expected to report earnings on November 2, 2026, with projected EPS of $4.84 and revenue of $3.4 billion. VRTX currently holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 26.69, trading at a premium to its industry average.

Vertex Pharmaceuticals stock declined 3.07% to $506.74 on October 1, 2026, underperforming the broader market gains. Despite positive earnings forecasts with expected EPS growth of 1.25% and revenue growth of 10.43% for the upcoming quarter, the stock has fallen 6.1% over the past month. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 27.73, trading at a premium to its industry average.

Healthcare sector is experiencing a significant rebound, with ETFs hovering near 52-week highs driven by double-digit earnings growth expectations, positive clinical trial results, attractive valuations, and expanding GLP-1 adoption. Major pharmaceutical companies reported promising drug-trial outcomes in oncology, obesity, and rare diseases, while M&A activity surged to nearly $284 billion. The sector is benefiting from a rotation out of overcrowded AI/tech trades into defensive growth.

The article compares two healthcare sector ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on 27 pharmaceutical companies, and iShares Biotechnology ETF (IBB), which covers 243 biotech stocks. IBB has a lower expense ratio (0.44% vs 0.58%) and outperformed over the past year (37.7% vs 33.9% return), but PJP offers higher dividend yield (0.92% vs 0.16%) and lower volatility. The choice depends on investor risk tolerance and portfolio goals.

The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.

CRISPR Therapeutics has transitioned to a commercial biotech with its approved gene-editing therapy Casgevy for blood disorders. The company has several promising pipeline candidates including CTX310 for cholesterol/triglycerides, zugo-cel for autoimmune diseases and blood cancers, and CTX611 as an anticoagulant. While significant clinical and commercial progress could drive substantial stock gains by 2030, investors face considerable risks including potential clinical trial failures and uncertain profitability economics for one-time gene-editing treatments.

Cathie Wood's ARK Invest purchased $3.4 million worth of CRISPR Therapeutics stock on consecutive trading days (Oct. 9 and Oct. 12), bringing her total holdings to $379.1 million. The investment reflects confidence in CRISPR's approved therapy Casgevy and promising pipeline candidates CTX-310 and CTX611, despite the stock declining 25% over the past year. CRISPR reported strong Q2 revenue growth of 151% year-over-year and maintains $2.36 billion in cash.

Meridian International Center announced the inaugural cohort of 25 leaders across business, technology, culture, sports, and state government recognized for shaping U.S. global influence. The group spans sectors including AI, space, medicine, energy, and finance, reflecting how American power is increasingly exercised beyond Washington through private sector innovation, international relationships, and cross-sector partnerships.

The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.

Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.